Björklund Pharma AS, a small wholly owned subsidiary of Bolna AS, develops evidence-based formulations based on biofactors and natural compounds to address complex medical conditions. It also invests in emerging biotech, medtech, and specialized life science ventures, serving as Bolna’s high-risk, high-reward satellite to capture scientific breakthroughs and niche innovation, while complementing the parent portfolio’s long-term stability and compounding growth.